P1/2, N=36, Completed, The University of Queensland | Not yet recruiting --> Completed

P2, N=27, Completed, Rennes University Hospital | Recruiting --> Completed

P3, N=750, Not yet recruiting, Milestone Pharmaceuticals Inc.

P4, N=92, Completed, Wake Forest University Health Sciences | Recruiting --> Completed | Trial completion date: Jun 2026 --> Nov 2024

P=N/A, N=12, Completed, Medical University of Vienna

The present research depicted that BIS and TMZ have the potential to protect the heart and provide therapeutic benefits by preventing acute heart injury induced by ATO. This is achieved by reversing the redox-sensitive pathway, reducing inflammation, and inhibiting apoptosis.

P1, N=55, Completed, University of Illinois at Chicago | Recruiting --> Completed | N=100 --> 55

P=N/A, N=618, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting

P3, N=300, Recruiting, Medical College of Wisconsin | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

Mechanistically, lacidipine targets calcium channels (CaV1.2/1.3) to inhibit Pyk2-JAK1-calmodulin complex-mediated IDO1 transcription suppression, which suppresses the kynurenine pathway and maintains the total nicotinamide adenine dinucleotide (NAD) pool by regulating NAD biosynthesis. These results reveal a new function of calcium channels in IDO1-mediated tryptophan metabolism in tumor immunity and warrant further development of lacidipine for the metabolic immunotherapy in breast cancer.

This study identified the role of key genes in thalamic hemorrhage-induced CPSP through snRNA-seq, providing a scientific basis for further exploration of the molecular mechanisms underlying CPSP.

P4, N=1, Completed, Vanderbilt University Medical Center | Enrolling by invitation --> Completed | Trial completion date: Jul 2025 --> Oct 2024 | Trial primary completion date: Jul 2025 --> Oct 2024

P=N/A, N=5047, Completed, Yuhan Corporation | Active, not recruiting --> Completed

P1/2, N=60, Recruiting, Minia University | Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Nov 2024 --> Feb 2025

P=N/A, N=50, Not yet recruiting, Seoul National University Hospital

P2, N=2, Terminated, Marshall University | N=234 --> 2 | Trial completion date: Dec 2024 --> May 2024 | Recruiting --> Terminated; The study has closed due to difficulty in enrollment.

To lay the groundwork for the future rational optimization of this promising class of compounds, the molecular bases of DM1 and DM2 activity were investigated by modelling their interaction with hCav3.1 channels. The calculated binding modes of DM1 and DM2 to hCav3.1 channels partially mirrored that of the selective Cav3.1 blocker Z944, paving the way for future lead optimization.

P1, N=19, Completed, Merck Sharp & Dohme LLC

In conclusion, diltiazem shows promise as a protective agent for liver inflammatory diseases. Further research is warranted to translate these preclinical results into effective strategies for improving liver health.

P=N/A, N=248, Not yet recruiting, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Tec

In conclusion, AMPK-mediated PI3K/mTOR, Nrf2, and NF-κB signaling pathways may all be involved in the therapeutic benefits of TRI for CIPN. These results indicate that TRI may be useful for reducing the side effects of CIPN and enhancing patient outcomes during cisplatin chemotherapy.

P2, N=138, Active, not recruiting, Medical University of Graz | Recruiting --> Active, not recruiting

P4, N=175, Completed, Prisma Health-Upstate | N=132 --> 175

P3, N=60, Recruiting, Ain Shams University

Our research has revealed that Dronedarone hydrochloride, an FDA-approved drug, is an SRC inhibitor that can suppress the growth of GC cells by blocking the SRC/AKT1 signaling pathway. It provides a scientific basis for use in the clinical treatment of GC.

Finally, we assessed the anti-cancer effects of DH in a pancreatic cancer mouse model and found that DH treatment suppressed pancreatic tumor development in vivo. Collectively, our investigation demonstrates that DH triggers pyroptosis in PDAC and proposes its potential effects on anti-PDAC growth.

P4, N=0, Withdrawn, Peking University Third Hospital | N=414 --> 0 | Not yet recruiting --> Withdrawn

The use of combination therapies, such as hydroxyurea alongside diltiazem, suggests more efficient and effective MG management compared to monotherapy. Since the efficacy of traditional therapies is limited in most cases due to resistance mechanisms in CSCs, further studies on the biology of CSCs are warranted to develop therapeutic interventions that are likely to be effective in MG. Consequently, improved diagnostic approaches may lead to personalised treatment plans tailored to the specific needs of each patient.

Male Swiss albino mice were injected with LPS (500 µg/kg, i.p) every other day alone or parallel with oral doses of either escitalopram (Esc) (10 mg/kg/day) or TMZ (20 mg/kg/day) for 14 days. Here we showed that TMZ is an affluent nominee for depression management via targeting TLR4/NF-κB and Nrf2/HO-1 pathways. Future research addressing TMZ-antidepressant activity in humans is mandatory to enroll it as a novel therapeutic strategy for depression.

P4, N=2, Enrolling by invitation, Vanderbilt University Medical Center | Initiation date: Aug 2024 --> Nov 2024

P2, N=129, Completed, Bial - Portela C S.A.

P=N/A, N=618, Not yet recruiting, Medical College of Wisconsin | Phase classification: P4 --> P=N/A

P4, N=56, Completed, Guangzhou Panyu Central Hospital; Guangzhou Panyu Central Hospital

P1, N=62, Completed, Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University

The cytometric analysis showed that the tested compounds (especially EDAG-8) are inhibitors of BCRP, MDR1, and MRP1 efflux pumps (more potent than the reference compounds-novobiocin, verapamil, and MK-571). An in silico study correlates with these results, suggesting that the compound with the lowest binding energy to these transporters (EDAG-8) has a more favorable spatial structure affecting its anticancer activity, making it a promising candidate in the development of a novel anticancer agent for future breast cancer therapy.

Furthermore, dronedarone suppressed the growth of ESCC in patient-derived tumor xenograft models in vivo. Thus, our study demonstrated that dronedarone could be repurposed as a CDK4/6 inhibitor for ESCC chemoprevention.

Lacidipine demonstrated a protective effect in UC, reducing inflammation and modulating key signaling pathways. These findings suggest that lacidipine could be a promising candidate for the treatment of UC.

P3, N=582, Completed, Eisai Ltd | Not yet recruiting --> Completed

Based on these novel findings, ESL has the potential for further experimental and clinical studies in glioblastoma.

P=N/A, N=217, Completed, Istanbul Medipol University Hospital | Trial completion date: Jun 2022 --> Aug 2024

We have reported that exo-C3-N-Dbn--Trp2 (13) as a lead ABCB1 inhibitor that is more effective than Verapamil...We correlate that the predictions based on the inhibitor interactions at the access tunnel provide clues about the design of improved ABCB1 inhibitors. This work lays the foundation for the design of a new class of inhibitors from a cyclo-L-Trp-L-Trp DKP scaffold.

P4, N=618, Not yet recruiting, Medical College of Wisconsin | Phase classification: P3 --> P4